Legend Biotech (Nasdaq: LEGN) reported a 100% objective response rate in six evaluable patients treated at the higher dose level with LB2501, its investigational in vivo CAR-T therapy for relapsed/refractory non-Hodgkin lymphoma, with complete responses in five of six. LB2501 is a CD19/CD20 dual-targeting in vivo CAR-T therapy designed to generate CAR-T cells directly within the patient following a single intravenous infusion, with Legend hoping to challenge the manufacturing and logistical constraints that have limited conventional CAR-T access. The data will be presented in a late-breaking oral presentation at the European Hematology Association (EHA) 2026 Congress in Stockholm on June 14.
The NCT07002112 study is an open-label, dose-escalation Phase I trial enrolling patients with relapsed/refractory B-cell malignancies. As of an April 1, 2026 data cutoff, 12 patients with R/R B-cell NHL had been treated across two dose levels; the efficacy headline derives from the six patients at dose level 2, with a median follow-up of 2.2 months (range 2.0–3.8). All six responses were ongoing at cutoff. Pharmacokinetic data showed dose-dependent in vivo CAR-T expansion, with CAR-T cells detectable in peripheral blood for up to 116 days — notable given that no lymphodepleting chemotherapy was administered prior to infusion. Safety across all 12 patients was characterized by infusion-related reactions in 75% (all Grade 2 or lower) and cytokine release syndrome in 66.7% (all Grade 2 or lower), with no dose-limiting toxicities, no serious adverse events, no deaths, and no immune effector cell-associated neurotoxicity syndrome. Grade 3 or higher events were limited to decreased lymphocyte and neutrophil counts.
Competitive context
The readout for LB2501 CAR-T in NHL readout matters principally because of what LB2501 does not require: ex vivo cell manufacturing, a REMS-certified treatment center, or lymphodepletion chemotherapy. Approved autologous CD19-targeting CAR-T therapies — Kite/Gilead's Yescarta (axicabtagene ciloleucel), Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel), and Novartis' Kymriah (tisagenlecleucel) — demand weeks of manufacturing, specialized infusion infrastructure, and inpatient monitoring for CRS and neurotoxicity, barriers that exclude a meaningful proportion of eligible patients. LB2501 instead uses Legend's proprietary TaVec lentiviral vector platform, engineered to transduce T-cells selectively in vivo following a single intravenous infusion, generating CAR-T cells directly within the patient. The dual CD19/CD20 targeting is designed to reduce the antigen-loss escape that has contributed to relapse after single-target CAR-T therapies.
The competitive field for R/R B-NHL is crowded. CD3×CD20 bispecific antibodies — AbbVie/Genmab's Epkinly (epcoritamab) and Roche's Columvi (glofitamab) — have demonstrated durable responses in late-line DLBCL and follicular lymphoma without the manufacturing burden of CAR-T, and their outpatient or fixed-duration profiles have made them a practical alternative for many centers. ADCs including Genentech/Roche's Polivy (polatuzumab vedotin) and ADC Therapeutics' Zynlonta (loncastuximab tesirine) occupy the third-line DLBCL space. Against this backdrop, an in vivo CAR-T approach that could be administered like a standard infusion — without prior lymphodepletion and without apheresis — would represent a meaningfully different operational profile, though cross-trial comparisons are limited by differences in patient populations, prior lines of therapy, and follow-up duration.
The reported 83% complete response rate compares favorably with outcomes reported for approved therapies in heavily pretreated B-cell lymphomas, although meaningful comparisons are limited by the very small sample size, short follow-up, and potential differences in patient populations.